Literature DB >> 24086071

Comparison of combined transcatheter arterial chemoembolization and radiofrequency ablation with surgical resection by using propensity score matching in patients with hepatocellular carcinoma within Milan criteria.

Yoshitaka Takuma1, Hiroyuki Takabatake, Youichi Morimoto, Nobuyuki Toshikuni, Takahisa Kayahara, Yasuhiro Makino, Hiroshi Yamamoto.   

Abstract

PURPOSE: To retrospectively compare the outcome of combined transcatheter arterial chemoembolization (TACE) and radiofrequency ablation (RFA) (hereafter, TACE-RFA) with that of surgical resection (SR) in patients with hepatocellular carcinoma (HCC) within the Milan criteria.
MATERIALS AND METHODS: Institutional review board approval and informed consent were obtained. From January 2000 to December 2010, 154 patients (mean age, 69.9 years; age range, 50-89 years; 107 men, 47 women) underwent TACE-RFA, and 176 patients (mean age, 66.9 years; age range, 29-83 years; 128 men, 48 women) underwent SR. Patients with HCC who underwent TACE-RFA or SR were enrolled if they met the following inclusion criteria: no previous HCC treatment, one HCC lesion no larger than 5 cm or up to three nodules smaller than 3 cm without vascular invasion or extrahepatic metastasis, and Child-Pugh class A or B disease. Cumulative overall survival (OS) and disease-free survival (DFS) rates were compared after adjustment with propensity score matching.
RESULTS: After this adjustment, OS rates were comparable between the groups (P = .393), but DFS was superior in the SR group (P < .048). Among patients with very early stage HCC (lesions <2 cm in diameter), OS and DFS rates in the SR group were significantly higher than those in the TACE-RFA group (P < .001 and P = .008, respectively). However, adjustment with propensity score matching yielded comparable OS and DFS rates between the two groups (P = .348 and P = .614, respectively).
CONCLUSION: TACE-RFA may be a viable alternative treatment for early-stage HCC when SR is not feasible. © RSNA, 2013.

Entities:  

Mesh:

Year:  2013        PMID: 24086071     DOI: 10.1148/radiol.13130387

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  35 in total

Review 1.  Combined locoregional treatment of patients with hepatocellular carcinoma: State of the art.

Authors:  Roberto Iezzi; Maurizio Pompili; Alessandro Posa; Giuseppe Coppola; Antonio Gasbarrini; Lorenzo Bonomo
Journal:  World J Gastroenterol       Date:  2016-02-14       Impact factor: 5.742

2.  Hepatectomy vs radiofrequency ablation for colorectal liver metastasis: a propensity score analysis.

Authors:  Huisong Lee; Jin Seok Heo; Yong Beom Cho; Seong Hyeon Yun; Hee Cheol Kim; Woo Yong Lee; Seong Ho Choi; Dong Wook Choi
Journal:  World J Gastroenterol       Date:  2015-03-21       Impact factor: 5.742

3.  Microwave ablation for the treatment of hepatocellular carcinoma that met up-to-seven criteria: feasibility, local efficacy and long-term outcomes.

Authors:  Yun Xu; Qiang Shen; Pei Liu; Zhongqi Xu; Panpan Wu; Zhenghua Lu; Yi Chen; Bin Huang; Guojun Qian
Journal:  Eur Radiol       Date:  2017-02-10       Impact factor: 5.315

4.  Combined transcatheter arterial chemoembolization and radiofrequency ablation versus hepatectomy for recurrent hepatocellular carcinoma after initial surgery: a propensity score matching study.

Authors:  Zhenwei Peng; Mengchao Wei; Shuling Chen; Manxia Lin; Chunlin Jiang; Jie Mei; Bin Li; Yu Wang; Jiaping Li; Xiaoyan Xie; Ming Kuang
Journal:  Eur Radiol       Date:  2018-03-13       Impact factor: 5.315

5.  Overview of Ablative Therapy for Hepatocellular Carcinoma.

Authors:  Steven C Rose
Journal:  Gastroenterol Hepatol (N Y)       Date:  2019-09

6.  Evaluation of CT vascularization patterns for survival prognosis in patients with hepatocellular carcinoma treated by conventional TACE.

Authors:  Davut B Hasdemir; Lukas Aguirre Dávila; Nora Schweitzer; Bernhard C Meyer; Armin Koch; Arndt Vogel; Frank Wacker; Thomas Rodt
Journal:  Diagn Interv Radiol       Date:  2017 May-Jun       Impact factor: 2.630

7.  Evaluation of the Heat Sink Effect After Transarterial Embolization When Performed in Combination with Thermal Ablation of the Liver in a Rabbit Model.

Authors:  Charles J Puza; Qi Wang; Charles Y Kim
Journal:  Cardiovasc Intervent Radiol       Date:  2018-07-23       Impact factor: 2.740

Review 8.  Supportive therapies for prevention of hepatocellular carcinoma recurrence and preservation of liver function.

Authors:  Taro Takami; Takahiro Yamasaki; Issei Saeki; Toshihiko Matsumoto; Yutaka Suehiro; Isao Sakaida
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

9.  Radiofrequency hyperthermia-enhanced herpes simplex virus-thymidine kinase/ganciclovir direct intratumoral gene therapy of hepatocellular carcinoma.

Authors:  Jianfeng Wang; Yaoping Shi; Zhibin Bai; Yonggang Li; Longhua Qiu; Guy Johnson; Feng Zhang; Xiaoming Yang
Journal:  Int J Hyperthermia       Date:  2016-09-20       Impact factor: 3.914

Review 10.  Recent Advances in Tumor Ablation for Hepatocellular Carcinoma.

Authors:  Tae Wook Kang; Hyunchul Rhim
Journal:  Liver Cancer       Date:  2015-07-17       Impact factor: 11.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.